Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States.
Progyny stock last closed at $27.08, down 0.15% from the previous day, and has increased 19.66% in one year. It has overperformed other stocks in the Health Information Services industry by 0.57 percentage points. Progyny stock is currently +68.2% from its 52-week low of $16.10, and -18.06% from its 52-week high of $33.05.
As of Sep 10, 2026, there are 76.73M shares of PGNY outstanding. The market cap of PGNY is $2.08B. In the past 24 hours, 894,000 PGNY shares were traded.
How to Buy Progyny Stock
Wondering how to invest in Progyny stock? Here's how.
Choose where to buy Progyny stock: You need to decide on an online brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you decide where to buy Progyny stock.
Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
Deposit money your brokerage account: Select your payment method and add your info.
Evaluate Progyny stock: The Progyny ticker symbol is PGNY. Is Progyny stock a good investment? Should you buy shares of PGNY? How do PGNY's underlying business fundamentals look? Do top analysts think Progyny is a good buy? Why has PGNY's stock price moved recently? (Hint: Our stock research website can help you figure out if PGNY is a good stock to buy).
Execute your PGNY buy order: Decide if you will purchase PGNY shares at the current market price or use a limit order to buy PGNY stock at a given price.
Get updates on your PGNY investment: Create a watchlist to monitor your investment in Progyny stock.
Step 1: Choose where to buy Progyny stock
You need an online brokerage account in order to access the NASDAQ market and buy PGNY shares.
A brokerage account enables you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
Access to world markets: From Technology to Healthcare, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by signing up for an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've chosen your brokerage, you'll need to fill out some personal info so you are able to buy PGNY stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Progyny stock
After you have identified the best place to buy Progyny stock, it's important to research their stock before you invest, so you truly understand the risk and upside.
Progyny shares data
PGNY Price
$27.08
1w %
1.77%
1y %
19.66%
5y %
-53.57%
P/E
28.21x
P/B
4.58x
P/S
1.61x
PEG
1.02x
Revenue
$1.31B
Earnings
$78.63M
Fore. Rev. Growth
8.14%
Fore. Earn. Growth
27.71%
Market Cap
$2.08B
Next Earnings
N/A
Next Dividend
N/A
Progyny Overview
WallStreetZen was built to help everyday investors do more accurate fundamental analysis quickly.
PGNY's operating cash flow of $201.25M allows it to safely service it's debt of $22.50M.
There are more short-term assets than long-term liabilities on the PGNY balance sheet.
PGNY earnings of $119.84M is not sufficient to cover its interest payments.
PGNY profit margin has gone up from 4.3% to 6% in the past year.
There are more short-term assets than short-term liabilities on the PGNY balance sheet.
Failed Financial Due Diligence Checks:
Total PGNY debt is higher than 5 years ago, relative to shareholder equity.
PGNY has a relatively high debt to equity ratio of 0.58.
Is it a good time to buy Progyny stock, according to analysts?
Out of 10 Equities analysts who research PGNY, the consensus analyst rating on PGNY is a Strong Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they financial advice.
Most Recent PGNY Analyst Forecasts
David Larsen, a top 21% analyst from BTIG maintains PGNY with a strong buy rating and raises their PGNY price target from $30.00 to $40.00, on Jul 24, 2026.
BTIG's David Larsen raised their price target on Progyny (NASDAQ: PGNY) by 33.3% from $30 to $40 on 2026/07/24. The analyst maintained their Strong Buy rating on the stock.
Progyny will report its Q2 2026 earnings on 2026/08/06.
Larsen made his price target move on the name in a Health Care IT and Digital Health sector preview note.
The analyst backgrounded that, overall, labor markets are fairly healthy, although some hospitals are reporting that the consumer is more cautious because of the costs of oil, inflation, the war in the Middle East and other concerns.
Richard Close, a bottom 3% analyst from Canaccord Genuity maintains PGNY with a strong buy rating and raises their PGNY price target from $30.00 to $36.00, on Jul 21, 2026.
Scott Schoenhaus, a bottom 2% analyst from KeyBanc maintains PGNY with a strong buy rating and raises their PGNY price target from $30.00 to $35.00, on Jul 13, 2026.
Michael Cherny, a top 12% analyst from Bank of America maintains PGNY with a strong buy rating and raises their PGNY price target from $29.00 to $31.00, on Jun 2, 2026.
Glen Santangelo, a bottom 9% analyst from Barclays maintains PGNY with a strong buy rating and raises their PGNY price target from $23.00 to $27.00, on May 18, 2026.
Last year, PGNY earnings were $78.63M. Over the last five year, PGNY's earnings have grown by 1.53% per year. This was slower than the Health Information Services industry average of 54.08%.
Last year, PGNY revenue was $1.31B. Over the last 5 year, PGNY's revenue has gone up by 23.84% per year. This was faster than the Health Information Services industry average of 19.15%.
No, Progyny doesn't provide an income stream by paying out dividends.
What do other traders have to say about PGNY?
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your PGNY buy order
There are two primary types of orders:
Market order: A market order is an order to buy or sell a stock at the best available price. Market orders are usually the best for newer investors.
Limit order: A limit order allows you to buy or sell a security at a specific price (or better). If you want to be certain you're buying or selling at a particular price, use a limit order.
Click the Open Trade button and your broker will place the order.
If you want additional help with buying stocks on eToro, click the how to video below:
As of Sep 10, 2026, it costs $27.08 to buy one share of Progyny stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.369 shares of PGNY.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.